API | tucotuzumab celmoleukin

tucotuzumab celmoleukin Report issue

Biologics mAb ADC Experimental

AACT ChEMBL MeSH

Active Ingredient History

NOW

Tucotuzumab celmoleukin is an anti-cancer drug. It is a fusion protein of a humanized monoclonal antibody (tucotuzumab) and an interleukin-2 (celmoleukin). ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules:

tucotuzumab celmoleukin

emd-273063

More Chemistry

Pharmacology

Mechanisms of Action:
- Epithelial cell adhesion molecule (Homo sapiens) ^UniProt
Multi-specific: No
Payload: IL2
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

emd-273063 | emd273066 | emd 273066 | emd-273066 | huks-il2 | ksa-interleukin-2 | tucotuzumab celmoleukin

Organizations (5)

Research & Development (5)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (7)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (7)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Colorectal Neoplasms (Phase 1)

Kidney Neoplasms (Phase 1)

Lung Neoplasms (Phase 1)

Ovarian Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 1)

Urinary Bladder Neoplasms (Phase 1)

Overview

Highest Phase: Phase 2
# of Trials: 3
# of Trial Organizations: 5

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue